3',4'-dihydro-1'H-spiro[cyclopentane-1,2'-naphthalen]-1'-one | 26673-27-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 四氢化萘
• 英文名称: 3',4'-dihydro-1'H-spiro[cyclopentane-1,2'-naphthalen]-1'-one
• 英文别名: 1-tetralone-2-spiro-1'-cyclopentane；3',4'-dihydro-spiro[cyclopentane-1,2'-naphthalen]-1'-one；3',4'-Dihydro-spiro[cyclopentan-1,2'-naphthalin]-1'-on；3'4'-dihydro-spiro[cyclopentane-1,2'(1'H)-naphthalen]-1'-one；1-Oxo-1,2,3,4-tetrahydro-naphthalin-2-spirocyclopentan；spiro[3,4-dihydronaphthalene-2,1'-cyclopentane]-1-one
• CAS: 26673-27-8
• 化学式: C₁₄H₁₆O
• 分子量: 200.28
• InChiKey: HCACYAWPHUFVKI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  15
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  3',4'-dihydro-1'H-spiro[cyclopentane-1,2'-naphthalen]-1'-one 生成 spiro[cyclopentane-1,2'-naphthalen]-1'-one
  参考文献：
  名称：

  The Rearrangement of Some Disubstituted Cyclic Ketones: An Unusual Dienone—Phenol Rearrangement¹

  摘要：

  DOI：

  10.1021/ja01125a035
• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 硫酸 作用下， 生成 3',4'-dihydro-1'H-spiro[cyclopentane-1,2'-naphthalen]-1'-one
  参考文献：
  名称：

  Sen-Gupta, Journal of the Indian Chemical Society, 1934, vol. 11, p. 389,393

  摘要：

  DOI：

文献信息

• [EN] 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE<br/>[FR] AGONISTES DE RÉCEPTEUR 5-HT2C ET COMPOSITIONS ET PROCÉDÉS D'UTILISATION
  申请人：ARENA PHARM INC

  公开号：WO2017023679A1

  公开（公告）日：2017-02-09

  Provided in some embodiments are compounds of Formula A, as defined herein, that modulate the activity of 5-HT2C receptor. Also provided in some embodiments are methods, such as, for weight management, inducing satiety, and decreasing food intake, and for preventing and treating obesity, antipsychotic-induced weight gain, type 2 diabetes, Prader-Willi syndrome, tobacco/nicotine dependence, drug addiction, alcohol addiction, pathological gambling, reward deficiency syndrome, and sex addiction), obsessive-compulsive spectrum disorders and impulse control disorders (including nail-biting and onychophagia), sleep disorders (including insomnia, fragmented sleep architecture, and disturbances of slow-wave sleep), urinary incontinence, psychiatric disorders (including schizophrenia, anorexia nervosa, and bulimia nervosa), Alzheimer disease, sexual dysfunction, erectile dysfunction, epilepsy, movement disorders (including parkinsonism and antipsychotic-induced movement disorder), hypertension, dyslipidemia, nonalcoholic fatty liver disease, obesity-related renal disease, and sleep apnea.

  在某些实施例中提供了一些符合本文所定义的A式化合物，其调节5-HT2C受体的活性。在某些实施例中还提供了一些方法，例如用于体重管理、诱导饱腹感、减少食物摄入，以及预防和治疗肥胖、抗精神病药物引起的体重增加、2型糖尿病、普拉德-威利综合征、烟草/尼古丁依赖、药物成瘾、酒精成瘾、病理性赌博、奖赏缺乏综合征和性成瘾，强迫症谱系障碍和冲动控制障碍（包括咬指甲和咬甲症），睡眠障碍（包括失眠、睡眠结构碎裂和慢波睡眠紊乱），尿失禁，精神障碍（包括精神分裂症、厌食症和暴食症），阿尔茨海默病，性功能障碍，勃起功能障碍，癫痫，运动障碍（包括帕金森病和抗精神病药物引起的运动障碍），高血压，血脂异常，非酒精性脂肪肝病，肥胖相关肾脏疾病和睡眠呼吸暂停症。
• Octahydrophenanthrene derivatives
  申请人：Hoffmann-La Roche Inc.

  公开号：US05385947A1

  公开（公告）日：1995-01-31

  Compounds of the formula: ##STR1## wherein R.sup.1 and R.sup.2 each individually are hydrogen or lower alkyl optionally substituted by aryl or C.sub.3-6 -cycloalkyl; R.sup.4 and R.sup.5 either both are hydrogen or both are halogen or one is hydrogen and the other is halogen, hydroxy, lower alkoxy, aryloxy or amino; and R.sup.3 is hydrogen or, where no primary or secondary amino group is present, alkanoyl; with the proviso that all the groups R.sup.1 through R.sup.5 cannot simultaneously be hydrogen; as well as pharmaceutically acceptable salts of compounds of formula I with acids have valuable pharmacodynamic properties as non-competitive NMDA antagonists and can accordingly be used as neuroprotectives.

  具有以下结构的化合物：##STR1## 其中R.sup.1和R.sup.2各自为氢或辅以芳基或C.sub.3-6-环烷基的低烷基; R.sup.4和R.sup.5要么都是氢，要么都是卤素，或者一个是氢另一个是卤素、羟基、低烷氧基、芳氧基或氨基; R.sup.3是氢或者在没有一级或二级氨基团的情况下是烷酰基; 但是要注意，所有的基团R.sup.1到R.sup.5不能同时为氢；以及具有药用酸盐的I式化合物具有有价值的药理作用性质，作为非竞争性NMDA拮抗剂，并因此可用作神经保护剂。
• The Synthesis of 4a-Aminoalkyl-1,2,3,4,4a,9-Hexahydrophenanthrenes. Versatile Intermediates for Potential CNS Drugs. I
  作者：B. Belleau、T. T. Conway、T. W. Doyle、L. Morris、W. Verbestel

  DOI：10.1139/v75-033

  日期：1975.1.15

  The synthesis of 1-aminoalkyl-1-hydroxy-2,2-tetramethylene-1,2,3,4-tetrahydronaphthalenes and their Wagner–Meerwein rearrangements into 4a-aminoalkyl-1,2,3,4,4a,9-hexahydrophen-anthrenes are described.

  本文描述了1-氨基烷基-1-羟基-2,2-四甲基-1,2,3,4-四氢萘烯的合成及其瓦格纳-梅尔文重排反应，生成4a-氨基烷基-1,2,3,4,4a,9-六氢苯并蒽。
• 5-HT2C receptor agonists and compositions and methods of use
  申请人：Arena Pharmaceuticals, Inc.

  公开号：US10272094B2

  公开（公告）日：2019-04-30

  Provided in some embodiments are compounds of Formula A, as defined herein, that modulate the activity of 5-HT2C receptor. Also provided in some embodiments are methods, such as, for weight management, inducing satiety, and decreasing food intake, and for preventing and treating obesity, antipsychotic-induced weight gain, type 2 diabetes, Prader-Willi syndrome, tobacco/nicotine dependence, drug addiction, alcohol addiction, pathological gambling, reward deficiency syndrome, and sex addiction), obsessive-compulsive spectrum disorders and impulse control disorders (including nail-biting and onychophagia), sleep disorders (including insomnia, fragmented sleep architecture, and disturbances of slow-wave sleep), urinary incontinence, psychiatric disorders (including schizophrenia, anorexia nervosa, and bulimia nervosa), Alzheimer disease, sexual dysfunction, erectile dysfunction, epilepsy, movement disorders (including parkinsonism and antipsychotic-induced movement disorder), hypertension, dyslipidemia, nonalcoholic fatty liver disease, obesity-related renal disease, and sleep apnea.

  在一些实施方案中，提供了如本文所定义的式 A 化合物，其可调节 5-HT2C 受体的活性。在一些实施方案中还提供了一些方法，例如，用于体重管理、诱导饱腹感和减少食物摄入量，以及预防和治疗肥胖症、抗精神病药诱导的体重增加、2 型糖尿病、普拉德-威利综合征、烟草/尼古丁依赖、药物成瘾、酒精成瘾、病态赌博、奖赏缺乏综合征和性成瘾）、强迫症谱系障碍和冲动控制障碍（包括咬指甲和嗜睡）、睡眠障碍（包括失眠、睡眠结构破碎和慢波睡眠紊乱）、尿失禁、精神障碍（包括精神分裂症、神经性厌食症和神经性贪食症）、老年痴呆症、性功能障碍、勃起功能障碍、癫痫、运动障碍（包括帕金森病和抗精神病药物诱发的运动障碍）、高血压、血脂异常、非酒精性脂肪肝、肥胖相关性肾病和睡眠呼吸暂停。
• Christol et al., Bulletin de la Societe Chimique de France, 1958, p. 248,254
  作者：Christol et al.

  DOI：——

  日期：——